WGS Stock Forecast & Price Target

GeneDx Holdings is projecting a positive growth outlook for their business, with a focus on utilizing exome and genome sequencing technology to advance precision medicine and improve healthcare outcomes. The recent policy update from major payers is supportive of this approach, further incentivizing clinicians to opt for the more comprehensive genome test. Though the company has recently faced a tough quarter due to a higher mix of genome testing than initially expected, we expect this issue to be remedied with time. With a solid market position, a growing sales force, and a potentially lucrative data strategy, GeneDx Holdings has the potential to see strong growth and continue to be a leader in the rare disease testing market.

GeneDx Holdings is facing headwinds in its core exome and genome business as it transitions to becoming a market leader in rare-disease testing lab services. The company's revenue and gross margin performance in the first quarter of 2026 missed expectations, primarily due to challenges in the non-core business and a lower-than-expected average selling price for its tests. In addition, there are uncertainties regarding the company's ability to monetize its rare disease database and successfully enter new markets like newborn screening and pediatric testing. Overall, the company's current financial performance and long-term growth plans raise concerns about its ability to deliver strong returns to investors in the future.